Myelodysplastic Syndrome Drugs Market Size to Exceed $3.58 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Myelodysplastic Syndrome Drugs Market Grown from 2024 to 2025?
In recent years, there has been significant expansion in the myelodysplastic syndrome drugs market. The market size is predicted to increase from $2.25 billion in 2024 to $2.47 billion in 2025, escalating at a compound annual growth rate (CAGR) of 9.8%. The considerable growth observed in the past can be credited to factors such as the aging population, strides made in diagnostics, MDS cases related to chemotherapy, a rise in cancer survival rates, as well as clinical research and the development of new drugs.
What Growth Rate Is Anticipated for the Myelodysplastic Syndrome Drugs Market in the Coming Years?
In the coming years, the market size for myelodysplastic syndrome drugs is forecasted to experience robust growth. The market is predicted to reach $3.58 billion by 2029, with a compound annual growth rate (CAGR) of 9.7%. This growth in the projected period can be credited to an increasing aging population, advancements in tailored therapies, enhanced comprehension of disease workings, heightened awareness and early detection, and the broadening of oncology research. Notable trends for the forecast period involve the optimization of erythropoiesis-stimulating agents, combination therapies, a rising emphasis on iron chelation treatment, regulatory approvals and market penetration, as well as patient-focused care models.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10675&type=smp
Who Are the Leading Companies in the Myelodysplastic Syndrome Drugs Market?
Major companies operating in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.
What Are the Key Drivers of the Myelodysplastic Syndrome Drugs Market?
The expected rise in cases of myelodysplastic syndrome is likely to fuel the expansion of the myelodysplastic syndrome drug market in the future. Myelodysplastic syndrome (MDS) encompasses a series of conditions marked by the abnormal growth and maturation of blood cells within the bone marrow. As a form of blood cancer, its primary impact is on the manufacture of healthy blood cells. Drugs for this condition are used for its treatment by restraining or modulating the immune system to reduce the need for red blood cell transfusions. For example, in October 2022, The American Journal of Managed Care, a journal based in the US, estimated that there are between 60,000 and 175,000 cases of myelodysplastic syndrome in the USA. Consequently, this surge in myelodysplastic syndrome cases is the key driver for the expansion of the myelodysplastic syndrome drug market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10675&type=smp
What Are the Key Market Segments in the Myelodysplastic Syndrome Drugs Industry?
The myelodysplastic syndrome drugs market covered in this report is segmented –
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide
2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine
3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products
What Are the Latest Trends in the Myelodysplastic Syndrome Drugs Market?
Prominent players in the myelodysplastic syndrome drugs industry are currently developing anti-telomerase drugs to engage with the telomerase enzyme with the aim of obstructing the unchecked division of irregular cells and therefore slowing down the progression of the disease. The efficacy of telomerase inhibitors in myelodysplastic syndrome drugs is demonstrated through their ability to inhibit telomerase enzyme and hinder the growth of irregular cells, potentially providing better results for patients. For example, in June 2024, Geron Corporation, an American biotech company, introduced rytelo (imetelstat), an FDA-authorized intravenous telomerase inhibitor designed for adults with low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and those with transfusion-dependent anemia who are unresponsive or ineligible for ESA. Rytelo, providing prolonged transfusion independence, improved hemoglobin levels, and satisfying an unfulfilled need in the myelodysplastic syndrome drugs industry, is characterized by its manageable safety profile.
Access The Full Report Here:
What Are the Key Regional Markets in the Myelodysplastic Syndrome Drugs Industry?
North America was the largest region in the Myelodysplastic syndrome drugs market in 2024.Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10675
This Report Delivers Insight On:
1. How big is the myelodysplastic syndrome drugs market, and how is it changing globally?
2. Who are the major companies in the myelodysplastic syndrome drugs market, and how are they performing?
3. What are the key opportunities and risks in the myelodysplastic syndrome drugs market right now?
4. Which products or customer segments are growing the most in the myelodysplastic syndrome drugs market?
5. What factors are helping or slowing down the growth of the myelodysplastic syndrome drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.